Reduced alpha diversity of the oral microbiome correlates with short progression‐free survival in patients with relapsed/refractory multiple myeloma treated with ixazomib‐based therapy (AGMT MM 1, phase II trial)
oleh: Heinz Ludwig, Bela Hausmann, Martin Schreder, Wolfram Pönisch, Niklas Zojer, Stefan Knop, Eberhard Gunsilius, Alexander Egle, Andreas Petzer, Hermann Einsele, Roman Hajek, Katja Weisel, Karl Jochen Krenosz, Alois Lang, Daniel Lechner, Richard Greil, David Berry
| Format: | Article |
|---|---|
| Diterbitkan: | Wiley 2021-02-01 |
Deskripsi
Abstract Alterations in the human microbiome have been linked to several malignant diseases. Here, we investigated the oral microbiome of 79 patients with relapsed/refractory multiple myeloma (MM) treated with ixazomib‐thalidomide‐dexamethasone. Increased alpha diversity (Shannon index) at the phylum level was associated with longer progression‐free survival (PFS) (10.2 vs 8.5 months, P = .04), particularly in patients with very long (>75% quartile) PFS . Additionally, alpha diversity was lower in patients with progressive disease (P < .05). These findings suggest an interrelationship between the oral microbiome and outcome in patients with MM and encourage a novel direction for diagnostic and/or therapeutic strategies.